Milrinon Carinopharm (Milrinone)

• Milrinone acts as a cardiac inotropic and vasodilator, used in acute heart failure syndromes.
• Acute decompensated heart failure: enhances myocardial contractility and reduces pulmonary congestion.
• Cardiogenic shock: provides rapid inotropic support and vasodilation to stabilize blood pressure.
• Bridge to cardiac transplantation: maintains adequate cardiac output while awaiting definitive therapy.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes, leading to accumulation of intracellular cyclic adenosine monophosphate (cAMP) in cardiac myocytes and vascular smooth‑muscle cells. Elevated cAMP increases calcium influx, strengthening myocardial contraction, while simultaneously causing vasodilation through smooth‑muscle relaxation, thereby improving cardiac output and reducing afterload.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hypotension: lowered blood pressure due to vasodilation.
• Tachyarrhythmias: premature beats or rapid heart rhythm.
• Headache: mild to moderate discomfort.
• Nausea: gastrointestinal upset.
• Flushing: warmth and redness of skin.
• Thrombocytopenia: reduced platelet count.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring intervention.
• Ventricular arrhythmias: life‑threatening heart rhythm disturbances.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Allergic reactions: rash, itching, or anaphylaxis.
• Liver enzyme elevation: potential hepatic injury.
• Bleeding complications: due to platelet effects.

• Milrinone requires careful monitoring and specific safety measures.
• Blood pressure monitoring: observe for hypotension during infusion.
• Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
• Renal function assessment: dose may need adjustment in severe renal impairment.
• Avoid in severe aortic stenosis: risk of excessive vasodilation.
• Use cautiously in hepatic dysfunction: altered drug metabolism.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma levels.
• Potent vasodilators (e.g., nitroprusside): may cause severe hypotension.
• Concurrent inotropes with pro‑arrhythmic potential: heightened risk of ventricular arrhythmias.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• Diuretics: synergistic effect on blood pressure.
• ACE inhibitors or ARBs: combined vasodilation requires BP monitoring.
• Digoxin: monitor for arrhythmias when both agents are used.